Walgreens Boots Alliance has set its sights on a cost-saving path as the pharmacy giant battles mixed financial results.

In its fiscal 2023 third-quarter results released on Tuesday, Walgreens revealed that profits had dropped to $118m, down from $289m in the same period from 2022. In light of this, the company adjusted earnings per share (EPS) guidance to $4.00 to $4.05 from $4.45 to $4.65.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

In a statement, CEO Rosalind Brewer blamed the “significantly lower demand for COVID-related services.” Walgreens, which operates the second-largest pharmacy store chain in the US, saw success during the Covid-19 pandemic when it offered a plethora of Covid-related services such as vaccines and tests. However, in May, the World Health Organisation (WHO) declared an end to the Covid-19 public health emergency – and now pharmacy chains are starting to see the reality of smaller profits in a post-pandemic world. 

In more positive financial results, Walgreens saw sales growth of 8.6%, to hit total sales of $35.4bn. The company pointed to a significant contribution from the retail pharmacy and healthcare segments.

The company stated it is taking actions to raise its “transformational cost management programme” target from $3.5bn to $4.1bn in total savings.

Shares in Walgreens dipped around 9% following the results.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Consumers continue to appreciate the value, convenience, and range of services provided by Walgreens and Boots. However, significantly lower demand for COVID-related services, a more cautious and value-driven consumer, and a recently weaker respiratory season created margin pressures in the quarter,” said Brewer.

“Our revised guidance takes an appropriately cautious forward view in light of consumer spending uncertainty, while still demonstrating clear drivers of a return to operating growth next fiscal year.”

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact